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http://dx.doi.org/10.1016/j.immuni.2014.05.013The inflammatory bowel diseases (IBDs) are among the most closely studied chronic inflammatory disorders
that involve environmental, host genetic, and commensal microbial factors. This combination of features has
made IBD both an appropriate and a high-priority platform for translatable research in host-microbiome
interactions. Decades of epidemiology have identified environmental risk factors, although most mecha-
nisms of action remain unexplained. The genetic architecture of IBD has been carefully dissected in multiple
large populations, identifying several responsible host epithelial and immune pathways but without yet a
complete systems-level explanation. Most recently, the commensal gut microbiota have been found to be
both ecologically and functionally perturbed during the disease, but with as-yet-unexplained heterogeneity
among IBD subtypes and individual patients. IBD thus represents perhaps the most comprehensive current
model for understanding the humanmicrobiome’s role in complex inflammatory disease. Here, we review the
influences of the microbiota on IBD and its potential for translational medicine.Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are the two main
forms of inflammatory bowel disease (IBD), both chronic im-
mune-mediated diseases with typical onset during young adult-
hood and a lifelong course characterized by periods of remission
and relapse. CD can involve any part of the gastrointestinal tract
but most commonly the ileum and proximal colon. UC is most
often localized to the descending colon but can occur pancoloni-
cally as well. Worldwide, there is a trend toward increasing inci-
dence of both UC and CD, with a recent systematic review
concluding that 75% of the studies of CD and 60% of those
with UC confirm a secular trend in incidence of disease (Molo-
decky et al., 2012). The modest concordance even in monozy-
gotic twins along with the relatively rapid temporal changes in
IBD incidence over the past six decades and the changes in
disease risk with migration suggest an important role for the
environment in disease pathogenesis. Although the disease is
strongly linked to the microbiome (see below) and the environ-
mental factors that can influence the microbiome, the details of
this relationship are complex.
The Complex Interplay of Host and Microbe in IBD
In this era of the $1,000 genome, it is difficult to appreciate the
degree to which our knowledge of the gut microbiota in IBD
has built on more than 50 years of microbiology and immu-
nology. Dawson and colleagues (Vince et al., 1972) cite a ‘‘resur-
gence of clinical interest in the role of the intestinal bacterial
flora’’ in 1972, just as has occurred in the past few years. Three
main developments prior to the advent of modern culture-inde-
pendent (i.e., sequencing-based as opposed to culturing-based)
studies sustained interest in the IBD microbiome: systematicculture-based profiles during early clinical management of IBD,
similar profiles of the gut microbial response to treatment, and
the advent of rodent genetic models recapitulating IBD symp-
toms. Investigation of IBD throughout the first half of the 20th
century tested and ruled out any number of individual microbial
pathogens as causative agents in the disease (Weinstein,
1961), but gut-resident microbes remained of interest due to
their exposure and uptake during ulceration and barrier breach
(Seneca and Henderson, 1950). Increasingly refined selective
media and anaerobic culture conditions throughout the 1960s
and 70s produced conflicting results for changes in gut microbial
load or profile during IBD (Cooke, 1967; Mallory et al., 1973;
Vince et al., 1972; Wensinck et al., 1981). These results in
many ways predicted those observed more recently with meta-
genomics: although slight changes in gut microbial residents
were present in some subsets of IBD patients, they were hetero-
geneous both among disease subtypes and among individuals
(Sartor, 1990).
In parallel, as treatments such as 5-aminosalicylic acid
(5-ASA) were introduced for the disease (Gorbach et al., 1968),
its effects on the microbiome were explored with similar
techniques. It was rapidly determined that compounds such as
salicylazosulphapyridine in particular were metabolized by gut
microbes (Cooke, 1969), due to differential product metabolite
profiles in germ-free and antibiotic-treated animals (Peppercorn
andGoldman, 1972). Again, though, changes inmicrobial load or
profile were modest (West et al., 1974), and the mechanism of
action of 5-ASAs and their effects on the gut microbiome remain
complex (Iacucci et al., 2010; Morgan et al., 2012). Treatments
for IBD provided another route by which the role of the gutmicro-
biome could be explored, however, because microbial changesImmunity 40, June 19, 2014 ª2014 Elsevier Inc. 843
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Reviewinduced by compounds alleviating disease might help elucidate
the still-missing host-microbe links.
Similarly, the third major development in IBD as a model for
complex microbial disease was the proliferation of genetically
modified animal systems in the 1980s and 90s (Sartor, 1995).
Once genetic ablation and, eventually, genetic replacement
systems joined chemical perturbations as rodent models for in-
testinal inflammation (Kontoyiannis et al., 2002; Rivera-Nieves
et al., 2003; Wirtz et al., 2007), it became relatively easy to test
whether changes in themicrobiome could shift disease outcome
in these IBD models. It was demonstrated that most IBD-like
symptoms were attenuated or abrogated by antibiotics and
germ-free conditions and restored or exacerbated by subse-
quent colonization (Rakoff-Nahoum et al., 2004; Rath et al.,
2001; Sadlack et al., 1993; Taurog et al., 1994). This behavior
in germ-free and subsequently recolonized inflammation models
provided, and continues to provide, one of the strongest argu-
ments for the close involvement of the gut microbiome in IBD.
The diversity of rodent genetic models that induced IBD-like his-
topathology helped the field rapidly converge on hypotheses
that remain central to investigations today: maintenance of
effector, regulatory, and T helper cell subsets; gut microbial
involvement; and complex, non-Mendelian genetics encom-
passing a range of microbial sensing, antimicrobial, inflamma-
tory, and innate and adaptive immune regulatory pathways
(Bouma and Strober, 2003; Rakoff-Nahoum et al., 2004). It is,
of course, important to remember that animal models rarely
perfectly recapitulate human disease, and these developments
were paralleled by further direct, translational evidence of
microbiome involvement such as improved clinical outcome in
the case of fecal stream diversion (Rutgeerts et al., 1991) and
the modulation of outcome and recurrence by antibiotics (Bern-
stein et al., 1980; Rutgeerts et al., 1995). By the time of the first
studies in IBD with culture-independent techniques comparable
to those available today, the potential molecular players were
thus well-established but as yet without molecular data on gut
microbial structure or function (Xavier and Podolsky, 2007).
Human Genetic Mechanisms of Microbial Interaction in
IBD
The past decade has seen substantial advances in our under-
standing of the pathogenesis of IBD, and in particular the com-
plex interaction with functional alterations in the immune system.
Genome-wide association studies have identified 163 distinct
loci that confer risk of or protection from the development of
CD and UC with a substantial portion of these loci (110 of 163)
common to both diseases (Jostins et al., 2012). The role of ge-
netics in the development of these diseases appears greater
for CD than UC, with roughly 2-fold greater variance explained
by associated loci. However, given that IBD-associated genetic
variants are present in many individuals who do not develop
disease, as well as the suggestion that classic loss-of-function
variants play only a disease initiation role in pathogenesis, a
full explanation of disease complexity will require substantially
more knowledge (Knights et al., 2013).
Many of the pathways in IBD are specifically known to have
heterogeneous effects when activated in different cell types,
and these cellular outcomes might be compounded to affect
disease. For example, in epithelial cells, autophagy pathways844 Immunity 40, June 19, 2014 ª2014 Elsevier Inc.play a key role in bacterial clearance; however, in macrophages,
the same autophagy genes affect the ability of cells to secrete
interleukin-1b (IL-1b), a key inflammatory mediator involved in
host defense (Lassen et al., 2014). Furthermore, IL-1b can act
through both innate lymphoid cells and CD4+ T cells to stimulate
IL-17 and IL-22 secretion and induce chronic intestinal inflam-
mation (Coccia et al., 2012), demonstrating that the same cyto-
kine can act on multiple arms of the immune system to promote
inflammation.
IBD-associated loci as a whole can be grouped into several
important pathways including the innate immune response,
maintenance of intestinal barrier function, autophagy, endo-
plasmic reticulum stress, microbial defense and antimicrobial
activity, goblet cell function, epithelial restitution, generation of
reactive oxygen species, pathways that determine tolerance
and training of innate immune cells, and maintenance of balance
between T helper 17 (Th17) cells and regulatory T (Treg) cells. For
example, several risk loci including HNF4A, CDH1, MUC19,
ITLN1, PTGER4, PTPRS, and GNA12 are all involved in pro-
cesses related to the maintenance of the epithelial barrier
(Khor et al., 2011), while ATG16L1, IRGM, and DAP influence
autophagy. The risk loci also highlight the importance of various
cytokine signaling pathways, in particular those mediated by
IL-10, IL-23, and IL-27. IL-23 in particular is influenced by several
of the risk loci—at least JAK2, STAT3, ICOSLG, TYK2, and
TNFSF15—and represents one of the major influences on the
disease.
The pathways affected by IBD risk (or protective) alleles some-
times appear to act in synergy with each other such that two
processes (for example, autophagy and endoplasmic reticulum
stress) operating within the same cell type result in an environ-
ment that promotes disease. Conversely, the same pathway
might affect different mechanisms in distinct cell types leading
to development of disease. For example, defects in autophagy
in epithelial cells lead to impaired Paneth cell function while a
similar autophagy defect in macrophages impairs IL-1b secre-
tion, resulting in a milieu that favors development of IBD. In addi-
tion, the synergy might be between a ‘‘first hit’’ represented by a
defect in a pathway and a ‘‘second hit’’ from a microbial trigger.
Variants in the HNF4A locus have consistently demonstrated
strong and specific associations UC, which along with the
CDH1 variants, suggest a key role for epithelial barrier integrity
in the pathogenesis of UC. Several genetic variants within the
human leukocyte antigen complex on chromosome 6p21 have
been strongly associated with UC. The most consistent associ-
ation with increased risk of IBD has been the DRB1*01:03 allele,
which is associated more strongly with UC than CD, whereas the
DRB1*04:01 allele is found less commonly in UC (Jostins et al.,
2012). These variations impact microbial recognition at the level
of antigen presentation and are clues to the involvement of the
microbiota in IBD.
Impaired NOD2 function has also been implicated in a poten-
tially distinct subtype ofmicrobial dysbiosis. This is supported by
a number of factors, including the dichotomous role of NOD2 in
the pathogenesis of CD: around one third of all patients with CD
have a deleterious mutation in NOD2 on at least one allele,
compared to around one tenth in the healthy population (Hugot
et al., 2001; Ogura et al., 2001). NOD2 status alone is thus a
very strong predictor of CD incidence, and the gene likely plays
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Figure 1. Disease Progression Can Be
Modeled as the Dynamical Response of a
Multistable, Multifactorial System
A systems-level perspective on health and disease
states in IBD and other microbiome-associated
conditions can be illustrated with an energy land-
scape model. The contours of the landscape (i.e.,
the depth of the healthy versus disease state)
determine how likely it is for an individual to
progress from one state to another. Individuals
with a lower ‘‘activation energy’’ to this landscape,
for example those carrying a NOD2 mutation,
might be predisposed to a shift in the microbial
community that correlates with IBD (see Section
‘‘Human Genetic Mechanisms of Microbial Inter-
action in IBD’’). Both healthy and disease states
are characterized by distinct microbial configura-
tions and immune responses. A disturbance
or perturbation, such as the introduction of an
inflammation-promoting pathobiont or treatment
with antibiotics, might cause the system to
transition to a new ‘‘disease’’ state. The underlying
contours of the landscape are determined by host
genotype, as well as environmental and physio-
logical factors. A susceptible individual (e.g.,
carrying disease risk alleles; below, in purple)
would be more sensitive to minor perturbations,
whereas a tolerant individual (bearing protective
regulatory variants; right, in green) would exhibit
robust behavior against strong stimuli.
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Reviewa key role in pathogenesis in a subset of patients. However, this
also means that there are other independent host factors with
strong combined effects.NOD2mutations are further associated
with clinical subtypes including ileal stenosis and surgical inter-
vention (Ananthakrishnan et al., 2014). IBD patients with NOD2
mutations have an increase in adherentmicrobes to the intestinal
mucosa (Swidsinski et al., 2002) and significant shifts in the rela-
tive abundances of Faecalibacterium and Escherichia species
(Frank et al., 2011). Thus, although the number and complexity
of genetic and microbial mechanisms involved in IBD pathogen-
esis appear to be large, resources and data are now available to
characterize them in human patient populations. If the route to
IBD pathogenesis is imagined as an energy diagram, then the
NOD2 risk allele, and other predisposing genetic alterations,
lower the ‘‘activation energy’’ required to bring the microbial
composition of the gut toward the disease state (Figure 1).
Gut Microbiome Observation and Association in Patient
Populations
Although the rise of culture-independent techniques for micro-
bial community characterization can be largely attributed to
the development of ‘‘high-throughput’’ sequencing platforms,
the earliest studies bridging this gap relied on gel electrophoresis
or Sanger sequencing to identify alterations to themicrobiome in
human IBD. This work continued to refine the insights begun by
culture-based techniques and set the stage for subsequent deep
metagenomic studies of microbiological and ecological shifts
during disease. For example, temporal temperature gradient
electrophoresis (TTGE) of 16S rDNA targeting a limited number
of large phylogenetic groups identified what is now a typical in-
crease in the enterobacteria (Martinez-Medina et al., 2006; Sek-
sik et al., 2003) and the reduction of anaerobes including the
Clostridia and Veillonellaceae (Joossens et al., 2011; Ott et al.,
2004) but (also like later studies) produced conflicting resultson whether microbial diversity in IBD was increased (Seksik
et al., 2003) or decreased (Bibiloni et al., 2006; Ott et al., 2004).
Terminal restriction fragment length polymorphism (T-RFLP)
characterization, including twin studies (Dicksved et al., 2008;
Willing et al., 2009), identified decreased diversity in both CD
and UC (Andoh et al., 2007). The technical difficulty of these
techniques initially restricted patient numbers to a few dozen
cases and controls, however, making their interpretation partic-
ularly challenging.
Soon after, though, a number of groups undertook Sanger
sequencing, initially using 16S rRNA hybridization followed by
fosmid cloning to compare CD, UC, and healthy individuals
from biopsies (Baumgart et al., 2007; Gophna et al., 2006; Prindi-
ville et al., 2004) and in stool samples (Manichanh et al., 2006).
These studies settled on more consistent trends, including the
enrichment of the Enterobacteriaceae (Baumgart et al., 2007;
Gophna et al., 2006) and a decrease in community diversity in
CD (Baumgart et al., 2007; Manichanh et al., 2006). The earliest
such investigations remained limited by sample numbers (gener-
ally under ten per group), with the first large-scale sequencing-
based study of the microbiota in IBD appearing in 2007 (Frank
et al., 2007). This used amplicon sequencing on a total of 190
biopsies from CD, UC, and control individuals. IBD samples
were depleted for Lachnospiraceae and Bacteroidetes and
enriched for Proteobacteria and Actinobacteria, and CD cases
in particular were more readily separable from control subjects
(and from UC) by means of gut microbial composition.
During the transition to high-throughput sequencing tech-
niques, an early pyrosequencing study on the 454 platform
that examined 40 twin pairs discordant for CD and UC identified
an increase in the Enterobacteriaceae and a decrease in
Faecalibacterium, consistent with previous studies (Willing
et al., 2010). A small number of array hybridization-based studies
were performed in a similar timeframe (Michail et al., 2012), againImmunity 40, June 19, 2014 ª2014 Elsevier Inc. 845
Figure 2. Interactions between the Gut
Microbiota and the Intestinal Mucosa in IBD
This illustration depicts the major alterations to the
composition of the gut microbiota in IBD, host
mechanisms to correct this dysbiosis, and their
functional consequences on the host mucosa. The
lumen (yellow), mucus layer (brown), epithelium
(purple brush-border-containing cells), and lamina
propria (bottom purple section) are shown. The
most consistent observations from microbial
profiling studies are shown (clades with decreased
abundance in IBD are in green, increased abun-
dance in red). Specific microbial mechanisms
supported by strong experimental evidence are
included. These mechanisms include the expan-
sion of the Treg cell compartment by microbially
produced butyrate and the inhibition of intestinal
natural killer T cell function by microbially pro-
duced sphingolipids to promote tolerance, as well
as epithelially secreted antimicrobial factors.
These mechanisms are grouped into themes,
displayed in gray boxes.
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Reviewechoing these enrichments for Proteobacteria and reduction in
Clostridia and overall diversity. The degree of agreement with
earlier work, especially with regard to a general decrease in di-
versity in CD and UC and shared shifts in abundance of specific
organisms, is remarkable. However, differences that do exist can
be attributed to differences in community profiling methods,
differences in protocols between laboratories, and differences
between the patient populations studied (including geographic,
genetic, and age-related differences). It is unclear whether the
changes to the microbiota described in these studies are a
causal factor or merely a consequence of intestinal inflammation
and IBD. However, several studies indicate that these microbial
shifts occur prior to, or in conjunction with, the onset of inflam-
mation and clinical phenotypes. A recent study by Gevers et al.
has examined a cohort of new-onset CD patients that includes
samples taken at the time of diagnosis, before the initiation of
treatment, and from multiple sections of the gut including ileal
tissue, rectal tissue, and stool samples (Gevers et al., 2014).
This study, the largest study of the IBD microbiome to date,
has added support to the most consistent subset of these
results: enrichment for the Enterobacteriaceae and depletion of
Clades IV and XIVa Clostridia during disease-associated inflam-
mation (Figure 2; Gevers et al., 2014). Furthermore, the study
found that these shifts in microbial abundance are even more
pronounced in patients who received antibiotics at the time of
sample collection, suggesting that antibiotics might exacerbate
CD-associated dysbiosis.
In addition to investigations of microbial ecology and composi-
tion during IBD, recent work has also begun to examine the
underlying molecular and metabolic mechanisms using culture-
independent techniques. The earliest shotgun metagenomic
study of the disease was included in the MetaHIT cohort (Qin
et al., 2010), which comprised mainly healthy individuals with a
subset of 21 UC and 4 CD patients. Although this provided a
wealth of raw data, minimal analysis was performed for the small
subpopulation of IBD patients, confirming mainly reduced diver-846 Immunity 40, June 19, 2014 ª2014 Elsevier Inc.sity (including both ecological and gene diversity) and an overall
separation from healthy microbiomes. The first investigation of
functional dysbiosis during IBD (Morgan et al., 2012) built on
this by including inferred microbial gene content from 231 sub-
jects and an additional 11 metagenomes. This study identified
enrichment in microbial pathways for oxidative stress tolerance,
immuneevasion, andhostmetabolite uptake,with corresponding
depletions in short-chain fatty acid (SCFA) biosynthesis and
typical gut carbohydratemetabolismandaminoacidbiosynthetic
processes. Intriguingly, similar microbial metabolic shifts have
been observed in other inflammatory conditions such as type 2
diabetes (Qin et al., 2012), suggesting a common core gut micro-
bial response to chronic inflammation and immune activation.
Host-microbial interactions in disease require molecular
mechanisms from the host as well, of course, and IBD has a his-
tory of deep investigation of human genetics that is detailed
below. Despite the strong suggestion of gut microbial interac-
tions in IBD-associated genetic loci (Jostins et al., 2012), few
studies have yet assessed any of these compositional or func-
tional responses in themicrobiome in tandemwith host genetics.
Modest effects have been observed for Eubacterium relative to
NOD2 risk alleles (Li et al., 2012) and Faecalibacterium with
FUT2 (Rausch et al., 2011), but the challenge of associating
many risk alleles with many microbial community members
can easily be underpowered in small cohorts. Mouse models
of these alleles (Kashyap et al., 2013; Spor et al., 2011)
and others described above tend to exhibit much stronger
dysbioses, but these have yet to be investigated in large human
populations.
Finally, systems-level views of gut microbial involvement in
IBD have only very recently and minimally begun to be explored.
Few analysis approaches yet exist that integrate transcriptional,
metabolic, and other ‘‘omics’’ perspectives on the gut micro-
biome with disease phenotype. Gut metatranscriptomes have
not yet been assessed during IBD, although during health
approximately half of microbial genes appear to be transcribed
Immunity
Reviewbasally, with the remaining half showing context-specific up- or
downregulation (Franzosa et al., 2014). The extensive contribu-
tion of even the healthy gut microbiota to metabolite production
and consumption makes stool metabolomics a particularly
promising route (McHardy et al., 2013), with early results
showing amino acid levels, SCFAs, and additional tricarboxylic
acid (TCA) cycle products perturbed in the IBD gut (and to a
lesser degree circulating) metabolome (Marchesi et al., 2007;
Ooi et al., 2011). Most current untargeted metabolite profiles of
the gut are derived from genetic (Sayin et al., 2013) or infectious
(Lu et al., 2012) mouse models of inflammation, which in such
extreme conditions tend to result in downregulation of typical
metabolites ranging from amino acids through lipids and bile
acids. One of the closest looks at the humanized (gnotobiotic)
murine gut microbiome and metabolome (Marcobal et al.,
2013) showed that fluctuations in metabolite levels are often
mirrored in microbiota composition, that they vary consistently
both in response to dietary shifts and interindividually, and that
these changes are somewhat preserved between human donors
and humanized murine hosts.
Metabolomic and metaproteomic assays of stool assess both
host and microbial products; while the origin of metabolites can
be difficult to determine, proteins from this mixed population can
typically be assigned to particular microbial or host (e.g., human
or mouse) sources. Peptide sequence specificity has been used
to separate host from microbial secreted proteins (Lichtman
et al., 2013), for example, showing extensive immune and meta-
bolic remodeling in response to varying microbial community
composition. Similarly in mice, the (primarily microbial) metapro-
teome appears to mirror the metatranscriptome quite closely
(McNulty et al., 2013), with most variability in an artificially colo-
nized system arising in response to the optimization of microbial
responses tonutrientavailability.During IBD, theonlymetaproteo-
mic studies to date have included either just six monozygotic twin
pairs concordant or discordant for CD (Erickson et al., 2012) or a
set of 9 UC and control subjects (Presley et al., 2012). Half of the
former subjects represented ileal CD patients with a particularly
extreme phenotype accounting for most of the variation in micro-
biome structure and protein expression, including depletion of
most typical carbohydrate utilization and amino acid metabolism
pathways incorrespondencewithoverall reducedmicrobial diver-
sity. The latter study found protein levels to better distinguish co-
litis subjects from controls than did microbial membership alone,
andassociatedproteinfluctuationswith14particularly informative
taxa, but only 87 proteins were surveyed in depth. Both studies
found substantial disruption of typical host-microbial crosstalk
during this extreme phenotype, and much deeper investigations
of the gut ecosystemwill be necessary to understand the commu-
nity-wide molecular mechanisms affected during IBD.
Causality and Mechanism in Mouse Studies
Mouse models have provided great insight into the role of the
microbiota in IBD because of a key advantage they hold over
patient cohorts: they can be easily perturbed both environmen-
tally and genetically to determine the causal mechanisms of
disease initiation and progression. Most patient cohort studies
examining the association of the microbiota with IBD are retro-
spective. By definition, these studies examine the composition
of the microbiota after disease onset rather than addressingshifts in microbial composition that might have contributed to
disease, as a prospective study would more directly address.
In some cases, the same alterations observed after disease
onset might also be present prior to disease or during progres-
sion. This is true, for example, in the Tbx21/ 3 Rag2/ UC
(TRUC) mouse model of colitis, in which Klebsiella pneumoniae
and Proteus mirabilis both correlate with outcome and elicit
colitis in Rag2/ and even wild-type adults (Garrett et al.,
2010; Garrett et al., 2007). Conversely, this assumption
does not hold true in ‘‘dnKO’’ (Il10rb/ and T cell-
restricted dominant-negative Tgfbr2) mice, where colonization
of antibiotic-pretreated IBD-susceptible animals with isolates
ofBacteroides thetaiotaomicron, but not commensal Enterobac-
teriaceae, resulted in robust colitis (Bloom et al., 2011). Surpris-
ingly, there was no difference in the fecal abundance of
B. thetaiotaomicron between colonized dnKO (colitic) versus
colonized Il10rb+/ (noncolitic) mice, although the Enterobacter-
iaceae were more than 100-fold enriched in the dnKO compared
to Il10rb+/ mice (Bloom et al., 2011), consistent with previous
results seen in studies of both IBD patients and mouse models
(Dicksved et al., 2008; Frank et al., 2007). Compositional
changes to the gut microbiota can thus be either causal,
responsive, or a mixture of the two in experimental models of
IBD, underscoring the importance of addressing the role of the
microbiota, and more specifically the question of causation, in
the context of murine intervention studies.
In order to establish the mechanisms of microbial influence in
IBD, and thereby causality, microbial molecular functions that
alter host physiology must be identified. The studies above fulfill
Koch’s postulates, for example, and demonstrate microbial cau-
sality in an animal model, but they remain a few steps removed
from demonstrating causation in human IBD (Figure 3). One of
the lessons from the recent renaissance in microbiome research
has been to adopt an ecological model of microbiology, rather
than the ‘‘one-microbe, one-disease’’ model that has been a
mainstay of infectious disease and microbiology research in
past decades. Although a collection of organisms within the
microbiome can have an additive or indeed synergistic effect
on physiology (Kim et al., 2007), these effects can be subdivided
into strain-level effects (and numerous models have been devel-
oped that establish a role for individual strains or species in IBD
[Elinav et al., 2011; Garrett et al., 2010; Kim et al., 2005; Powell
et al., 2012]) and further subdivided into individual molecular
effects imparted by those organisms. Therefore, an important
recent step forward in understanding the function of the
microbiome in IBD has been to ‘‘drill down’’ into human micro-
biome-wide association studies with detailed molecular and
biochemical analyses in mouse models to decipher the cellular
and molecular circuitry that connects microbial products to
host signaling pathways and physiological responses.
The concept of reducing the effect of a complex microbial
community to an individual molecule with a defined host physio-
logical response is well illustrated by a recent collection of
studies examining the effects of SCFAs on colonic T cell popula-
tions. Individual bacterial strains isolated from healthy human
stool were assayed for the induction of CD4+FOXP3+ Treg cells,
identifying a collection of 17 strains with strong activity that
belonged to Clades IV, XIVa, and XVIII of the Clostridia (Atarashi
et al., 2013). Because these groups of Clostridia are potent SCFAImmunity 40, June 19, 2014 ª2014 Elsevier Inc. 847
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Figure 3. Modified Hill’s Criteria for
Assessing a Causal Role for the Gut
Microbiota in IBD
Experimental design considerations for a study of
the role of the gut microbiota in IBD should include
factors that directly address causation. Shown
at the top are five of the Hill’s criteria that are
most applicable to gut microbiota studies in IBD,
including biological plausibility (Does the study
provide evidence of amechanistic link between the
microbe or community of microbes and disease?),
association strength (Is there a strong statistical
association between the microbe or community of
microbes and disease?), association specificity (Is
the microbe or community of microbes also known
to be involved in other unrelated diseases or is
there high specificity for the disease in question?),
association consistency (Do independent labora-
tories report the same association?), and associa-
tion temporality (Does theputativedisease-causing
microbe or community of microbes appear at the
anticipated time prior to the onset of disease?).
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imparted primarily by this group of metabolites (Narushima
et al., 2014), and indeed independent studies found G protein-
coupled receptor 43 (Gpr43, now known as Ffar2)-mediated
(Maslowski et al., 2009) proliferation of Treg cells in response
to SCFAs (Arpaia et al., 2013; Furusawa et al., 2013; Smith
et al., 2013), resulting in reduced colitis (Furusawa et al., 2013;
Smith et al., 2013) (see Figure 2). Furthermore, the gut microbial
product niacin enables colonic macrophages and dendritic cells
to induce the differentiation of Treg cells and suppress colitis and
intestinal cancer in a manner dependent on Gpr109a, now
known as Hcar2 (Singh et al., 2014).
To highlight the need for additional mechanistic studies on the
microbiome, prior to the recent work on SCFAs and Treg cell
function, the only other microbial product that has been directly
linked to a beneficial effect on host immune function has been
polysaccharide A (PSA) produced by the commensal bacterium
Bacteroides fragilis (Mazmanian et al., 2005). PSA interacts with
Toll-like receptor 2 primarily on antigen-presenting cells and
is processed and presented by the major histocompatibility
class II complex to activate CD4+ T cells (Round et al., 2011),
which can result in both immunoprotection through IL-10
secretion, or proinflammatory responses via interferon-g secre-
tion (Dasgupta and Kasper, 2013). B. fragilis protects mice from
Helicobacter hepaticus-induced colitis in a PSA-dependent
manner (Mazmanian et al., 2008). A recent study by Kasper
and colleagues suggests that the immunomodulatory action
of B. fragilis might not be a function of PSA alone, but also
sphingolipids (An et al., 2014). Sphingolipids produced by
B. fragilis negatively regulate intestinal natural killer T cells and
prevent their excessive activation during oxazolone-induced
experimental colitis, thus contributing to the maintenance of
host immune balance (An et al., 2014; see Figure 2).
Despite these successes in unraveling the molecular mecha-
nisms of IBD induction in mice, it is important to remember that
nearly all mouse IBD studies are performed in the context of the
complete deletion of a gene, a strong chemical colitogen, a highly
controlled anduniformmicrobial environment, and inmany cases
a combination of all three of these nonphysiological factors. Hu-
man IBD does not involve such strong genetic and environmental
perturbations, and these systems thus might or might not be848 Immunity 40, June 19, 2014 ª2014 Elsevier Inc.appropriate models for particular components of the human dis-
ease.Recently, amousemodel of theT300Amutation in theauto-
phagy gene Atg16l1 showed defective clearance of the ileal
pathogen Yersinia enterocolitica and sustained inflammatory
cytokine response (Lassen et al., 2014; Murthy et al., 2014).
The future use ofmousemodels that replicate precise human ge-
netic alterations discovered from IBD genome-wide association
studies in the context of IBD-relevant alterations to the micro-
biota will be an important step forward in modeling human IBD.
Gaps, Challenges, and Next Steps
The gutmicrobiome’s potential as a candidate biomarker for host
health in IBD has not yet been fully explored. As a cross-sectional
diagnostic indicator for IBD, colonic microbial profiles provide
only modest delineation between patients and asymptomatic
controls (Dicksved et al., 2008; Frank et al., 2007; Morgan et al.,
2012), ruling out a simple, universal ‘‘magic bullet’’ for early diag-
nosis, although optimistically this need not be the case in all com-
plex inflammatory conditions. Instead, heterogeneity among CD,
UC, and subtypes within them (e.g., ileal CD) suggests that care-
fully chosen microbial samples could, for example, be used to
improve classification under high-risk conditions such as ileal
pouch surgery (Tyler et al., 2013). Similarly, little work has yet
been done on using gut microbial readouts to classify patients
with respect to expected response to treatment. In CD, for
example, 5-ASAs are a relatively mild first-line therapy to which
some patients respond well and others only minimally; a clear
microbial predictor of patient response would eliminate the
need for a lengthy step-up process (Kamm, 2004; Peyrin-Biroulet
et al., 2013). Longitudinal studies have not yet been carried out
with appropriate designs to discover prognostic microbial bio-
markers of treatment response, flare onset and recovery, or dis-
ease severity, however. Likewise, it is not yet clear for IBD or for
other inflammatory conditions whether the ‘‘right’’ biomarkers, if
any exist, will be derivable from stool, mucosal biopsies, or other
sample types, or whether they will consist of one or a few micro-
bial abundances, overall ecological profiles, gene expression,
peptides, metabolites, or other biomolecular markers.
Likewise, ecological therapies leveraging the microbiome are
still in their infancy in IBD, as in nearly all complex, chronic con-
ditions. Successes such as fecal microbiome transplants for
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Figure 4. Experimental Design Considerations in Gut Microbiome Studies, with IBD as an Example
The development of gutmicrobiome study designs in IBD can serve as an example for other gutmicrobial dysbioses, as they demonstrate the interplay of biology,
sample availability, and financial constraints. Observations typically start with ‘‘top down,’’ descriptive studies of the stool or (less often due to availability)
mucosal microbiome in modestly sized populations. ‘‘Bottom up’’ molecular detail can be added efficiently by perturbation studies in cell lines, but these are
limited in relatability to primary populations. Two-stage study designs offer cost-effective scalability to larger cohorts (Tickle et al., 2013), which are also better
powered for genetic profiling. Patient samples can be used to derive primary cell lines (Miyoshi and Stappenbeck, 2013) or organoids (Sato et al., 2011) for
controlled perturbations that more closely recapitulate in vivo conditions. Likewise, stool samples can be transferred to gnotobiotic animal models (Goodman
et al., 2011) to determine the causal contribution of the microbiome to phenotype, leading in more complex designs to longitudinal perturbations in multiple
genetic models or environmental conditions. Finally, in-depth profiling of moderately sized patient populations over time can provide multiple views on gut
microbial contributions to phenotype. This remains cost effective when combinedwith staged study design (i.e., not all assays are run on all samples), and sample
availability and perturbations such as treatment changes are typically contingent on clinical care.
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ReviewClostridium difficile infection (Borody and Khoruts, 2012) high-
light the great potential of microbial modulation under such
circumstances, but early results for this broad-brush approach
in IBD have been mixed (Aroniadis and Brandt, 2013; Sha
et al., 2014; Smits et al., 2013). Similarly, ‘‘untargeted’’ probiotics
tend to have significant but small beneficial effects in IBD (Leone
et al., 2013; Whelan and Quigley, 2013), suggesting that microbi-
al communitymodulation has the potential to improve outcome if
the correct, specific pressures can be discovered and applied.
Some of these might be positive, in the sense of probiotically
restoring one or more microbial taxa, or providing a selective
growth advantage to underrepresented clades by means of
diet, pharmaceuticals, or prebiotics (DuPont and DuPont,
2011). Others might be negative, selecting against community
members by the same mechanisms or through the development
of particularly narrow-spectrum antibiotics (Lemon et al., 2012).
Some of the most successful current molecular treatments in
cancer—another complex, multifactorial disease—were devel-
oped to inhibit or promote extremely specific molecular compo-
nents of dysregulated pathways (Deininger et al., 2005; Perez
and Baweja, 2008). A comparable level of specificity might be
needed to treat complex dysbioses, either targeting pathway
components intracellularly in one or more host or microbial cell
types, or extracellularly by depleting, competing with, or supple-
menting native metabolites or signaling molecules. The firststeps toward these goals have already been taken by investi-
gating the bioactivity of unique natural products in the gut
(Holmes et al., 2012; Lemon et al., 2012), but none have as yet
been developed with specific therapeutic potential in IBD.
The development of study designs for diagnostic or therapeu-
tic applications of the gut microbiome in IBD serves as a model
by which other microbially linked conditions can be investigated
(Figure 4). Most study design considerations in the microbiome
vary along several axes, each of which must be considered to
identify experimental components appropriate for the conditions
and hypotheses at hand.
1. Clinical relevance versus experimental control. Any transla-
tional study is, at best, more variable in a patient population
relative to a laboratory environment, but typically more likely to
provide results that are applicable clinically.
2. ‘‘Top down’’ versus ‘‘bottom up’’ information. Many obser-
vational studies of the microbiome are driven by 16S profiling
alone, resulting in descriptive information. This can be comple-
mented by assays that are typically more expensive and/or
time-consuming but which provide molecular or mechanistic
detail.
3. Host versus microbial profiling. Assays such as 16S
profiling or metagenomic and metatranscriptomic sequencing
of stool samples yield information primarily on microbial
activity. Conversely, transcriptional profiling of mucosal biopsiesImmunity 40, June 19, 2014 ª2014 Elsevier Inc. 849
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Reviewdescribes the human host’s activity. Other assays, such as stool
metabolomics and proteomics, can capture molecular activities
originating from either source.
4.Sample availability. In patient populations, stool samples are
more readily accessible than biopsies but are still difficult to
collect in bulk from very large cohorts.
5. Cost. Staged study designs are particularly appropriate for
the microbiome (Tickle et al., 2013) because they allow the ben-
efits of large cross-sectional profiles combined with molecular
detail derived from a subset of individuals, conditions, or time
points.
In addition to these microbiome-focused choices, other study
design considerations are shared with any high-throughput,
translational biology. The care that must be taken during both
study design and analysis to ensure reproducibility cannot be
overemphasized (Peng, 2011). Microbiome assays are currently
particularly sensitive to batch effects and interpopulation differ-
ences (Koren et al., 2013; Leek et al., 2010), in addition to the
multiple hypothesis testing issues common to any high-dimen-
sional analysis (Sandve et al., 2013). Additionally, like other
complex, polygenic, personalized conditions such as cancer,
the generalizability of any finding to other populations must be
considered (Yatsunenko et al., 2012), as should heterogeneity
among disease subtypes (Cancer Genome Atlas, 2012; Morgan
et al., 2012; Willing et al., 2009).
Studies of the gut microbiome’s role in complex disease must
also contend with a wide range of time scales, in contrast to
studies focusing solely on human genetics or transcriptional
responses. Several of these are due to distinct molecular pro-
cesses: host genetics are fixed over the course of a lifetime,
host epigenetic modifications can occur over days to months
(Sasai et al., 2013), changes in microbial populations due to
doubling times can likewise take anywhere from days to months
(Dethlefsen and Relman, 2011; Gajer et al., 2012), and host or
microbial transcription, metabolism, or protein expression can
change in seconds to minutes. However, other temporal consid-
erations are dictated by larger-scale processes and phenotypes.
Transit times in response to dietary shifts occur over hours to
days, for example (David et al., 2014), and in IBD evidence sug-
gests differences both between pediatric and adult cases and
between new-onset and established disease (Gevers et al.,
2014). The microbiome also changes rapidly during early devel-
opment, particularly during infant colonization (Koenig et al.,
2011; Sharon et al., 2013; Yatsunenko et al., 2012). Microbiome
studies must thus identify the correct temporal scale(s) at which
to operate for any particular hypothesis.
Finally, although stool samples provide one of themost readily
accessible windows into the gut microbiome for most studies,
the snapshot they offer is distinct from that provided by mucosal
biopsies, lavages, or other sample types (Li et al., 2011; Morgan
et al., 2012; Stearns et al., 2011; Swidsinski et al., 2002). Stool is
regularly characterized by an expansion of Firmicutes relative to
Proteobacteria and Bacteroidetes at the mucosal surface, and
the heterogeneity of the microbiome within individual stool sam-
ples is not yet well understood. Additionally, the biogeography of
the intestinal tract itself influences microbial community struc-
ture and function, with dramatic differences in pH,microbial den-
sity, and composition between the small and large intestine and
in a more gradual continuum across the colon (Eckburg et al.,850 Immunity 40, June 19, 2014 ª2014 Elsevier Inc.2005; Morgan et al., 2012; Peterson et al., 2008; Stearns et al.,
2011). Diffusion rates of microbes, microbial metabolites, and
host biomolecules through the mucosa and lumen are generally
not well characterized, making their biogeographical sources
and sinks somewhat unclear. The fecal microbiome might thus
be viewed as a somewhat noisy function of the mucosal
microbiome (Gevers et al., 2014), providing a more clinically
convenient but sometimes less interpretable picture of microbial
activity in situ at the mucosa.
Mouse models of IBD, although coming with the slate of draw-
backs typical of any model system, were one of the first indica-
tors of the gut microbiome’s crucial role in the disease and
continue to be critical for understanding its molecular mecha-
nisms. In mouse models, control of gut community composition
allows the membership and molecular function of gut microbes
to be closely linked and studied in tandem. It also allows for
perturbations that affect immune function to be examined in
the context of defined shifts in the microbial community.
Focusing on well-defined microbial gene functions and metabo-
lites under such conditions is more experimentally reproducible,
particularly when gnotobiotic transfer from individual human
donors can be replicated multiple times, for example. Finally,
microbial gene functions and pathways, and their effects on
mucosal immune function, shown to contribute to IBD in such
models can be brought back to the clinic as potential therapeutic
molecules or molecular targets.
Though it is a field with a long history, studies of the role of the
gut microbiota in IBD have made large strides within the past
half-decade. The field has moved from shallow 16S sequence-
based community profiling studies to ‘‘high resolution’’ deep
metagenomic characterizations at the strain and gene level,
both in mouse models and in increasingly larger and more
sophisticated human cohort studies. The focus has moved
from taxonomic descriptive studies to detailed, metagenom-
ics-based functional characterizations that have been related
to its effects on the host immune response. In the coming half-
decade, the focal point of gut microbiota studies in IBD will shift
from broad functional characterizations toward the identification
of specific effectormolecules includingmicrobial structural com-
ponents, intracellular and secreted metabolites and proteins,
and other regulatory and signaling components produced from
the dialog that is transpiring between the gut microbiota and
the host immune system. Adopting amolecular-centric perspec-
tive in assessing the role of the microbiome in IBD will provide a
fine-grained resolution of this dialog, and it has the potential to
enable numerous therapeutic avenues to tackle this disease.
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